Inogen Announces Preliminary Fourth Quarter and Full Year 2022 Revenue Within Company Expectations
Inogen, Inc. (Nasdaq: INGN) has released preliminary revenue estimates for Q4 and full year 2022, projecting revenues between
- Preliminary Q4 2022 revenue estimates range from $87.5 million to $88.5 million, indicating growth of 14.5% to 15.8%.
- Full year 2022 revenue expected between $376.7 million to $377.7 million, reflecting a growth of 5.2% to 5.5%.
- Preliminary results meet previously projected guidance for Q4 of $87 million to $92 million.
- Foreign exchange fluctuations expected to negatively impact Q4 revenue by $1.3 million and full year revenue by $5.3 million.
- CEO mentioned ongoing macroeconomic pressures affecting business operations.
Inogen to Present at J.P. Morgan Healthcare Conference This Week
Inogen to Announce Fourth Quarter and Full Year 2022 Financial Results on
The Company estimates preliminary, unaudited total revenue in the fourth quarter of 2022 to be in the range of
Foreign exchange fluctuations are estimated to have a
These preliminary, unaudited results are within the previously projected fourth quarter guidance range of
“Despite the prevailing macroeconomic pressures and headwinds resulting from our efforts to continue upgrading the operating disciplines in our DTC commercial team, preliminary fourth quarter 2022 results came in within the expectations we had shared during our third quarter earnings call,” said
Inogen to Present at
Quarterly Conference Call Information
Inogen will issue fourth quarter and full year 2022 financial results after the market closes on
Individuals interested in listening to the conference call may do so by dialing:
US domestic callers (877) 841-3961
Non-US callers (201) 689-8589
Please reference Inogen to join the call. To listen to a live webcast, please visit the Investor Relations section of Inogen's website at: http://investor.inogen.com/. This webcast will also be archived on the website for 6 months.
A replay of the call will be available approximately three hours after the live webcast ends and will be accessible through
Inogen has used, and intends to continue to use, its Investor Relations website, http://investor.inogen.com/, as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD. For more information, visit http://investor.inogen.com/.
About Inogen
For more information, please visit www.inogen.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, Inogen’s expectations regarding its preliminary, unaudited revenue, for full year and fourth quarter 2022; expectations for future growth and profitability; expectations related to our sales force and productivity; and our expectations related to management of operating expenses. Any statements contained in this communication that are not statements of historical fact may be deemed to be forward-looking statements. Words such as “believes,” “anticipates,” “plans,” “expects,” “will,” “intends,” “potential,” “possible,” and similar expressions are intended to identify forward-looking statements. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including but not limited to, risks arising from the possibility that Inogen will not realize anticipated revenue; risks related to the Company’s supply chain and limited availability of parts used in our POCs, the risk of further slowdowns or temporary halts to production, or cost inflation for such components; the impact of changes in reimbursement rates and reimbursement and regulatory policies; and the possible loss of key employees, customers, or suppliers; the risk that expenses and costs will exceed Inogen’s expectations. In addition, Inogen's business is subject to numerous additional risks and uncertainties, including, among others, risks relating to market acceptance of its products; competition; its sales, marketing and distribution capabilities; its planned sales, marketing, and research and development activities; interruptions or delays in the supply of components or materials for, or manufacturing of, its products; seasonal variations; unanticipated increases in costs or expenses; and risks associated with international operations. Information on these and additional risks, uncertainties, and other information affecting Inogen’s business operating results are contained in its Annual Report on Form 10-K for the year ended
The amounts set forth above are preliminary estimates. Inogen is in the process of finalizing its results of operations for the year ended
View source version on businesswire.com: https://www.businesswire.com/news/home/20230110005495/en/
ir@inogen.net
Source:
FAQ
What are Inogen's preliminary revenue estimates for Q4 2022?
How did Inogen perform in revenue for the full year 2022?
When will Inogen announce its financial results for Q4 and full year 2022?
What is the expected impact of foreign exchange on Inogen's revenue?